The aim of this study was to investigate the potential prognostic value of preoperative serum prostate-specific antigen levels adjusted for total tumor volume (PSA-TTV density) for outcome following radical prostatectomy for prostate cancer by retrospective review in 268 patients. Lower PSA-TTV density was not only associated with a significantly higher risk for biological failure (bF), systemic failure and cancer death but also an independent predictor for bF (hazard ratio, 6.3). Therefore, these data suggest that there are subsets of prostate cancer with lower PSA secretion levels, and this phenotype is associated with a higher risk of failure after surgery.
Introduction
Many clinicopathological variables have been shown to correlate with the likelihood of biological failure (bF) after radical prostatectomy, with pathological stage known to be most influential. 1 However, it is still unclear which additional variable or combination of variables will most accurately predict tumor recurrence.
The advantage of prostate-specific antigen (PSA) density over PSA for predicting adverse pathological findings and bF after definitive therapy for prostate cancer is controversial. 2, 3 Confounding factors include the effects of benign prostatic hyperplasia (BPH) within the malignant gland: not only may the gland contain varying amounts of PSA-producing BPH tissue, but correlation between the volume of BPH and serum PSA may be poor. 4 On the other hand, a negative correlation between serum PSA and Gleason score adjusted for tumor volume has been reported. 4 Although PSA levels do not necessarily reflect tumor burden and pathological stage, 4, 5 low PSA values in the presence of a large tumor may represent an aggressive phenotype irrespective of the amount of BPH.
These considerations led us to investigate the significance of PSA adjusted for total tumor volume as a predictor of advanced pathological findings and clinical outcome after radical prostatectomy.
Patients and methods

Patients
The study population comprised 268 evaluable men treated with radical retropubic prostatectomy and bilateral pelvic lymph node dissection, without neoadjuvant therapy of any type, at three medical schoolaffiliated hospitals (Jikei University Hospital (n ¼ 69), Kitasato University Hospital (n ¼ 137) and Kurashiki Central Hospital (n ¼ 63)) between January 1988 and November 2002. Several different PSA assays (Eiken polyclonal radioimmunoassay (Eiken, Tokyo, Japan), Dainapack IMx PSA assay (Dinabot, Tokyo, Japan), AxSYM PSA assay (Dinabot)) were used at Kitasato and Kurashiki during this period. 6 All values at Jikei were measured by E test Tosoh IIPA (Tosoh Co., Tokyo, Japan). For uniformity, Eiken PSA data were inter-converted as follows: (IMx PSA) ¼ 1.39 Â (Eiken PSA)À1.02. 7 Results of other assays were not inter-converted because they are considered virtually identical.
Staging and pathological examination
All patients underwent pretreatment evaluation with digital rectal examination, chest radiograph, computerized tomography or magnetic resonance imaging scan of the abdomen and pelvis, and bone scanning. Clinical stage was determined according to the updated 2002 version of the unified tumor node metastasis system. 8 Prostatic volume was determined at the time of transrectal ultrasonography-guided biopsy with the use of following formula: prostate length Â width Â height Â p/6.
The whole mount step-sectioning technique was used in these patients. All hematoxylin & eosin pathological slides of radical prostatectomy specimens were reviewed by a single pathologist (SK) and tumor grade was assigned based on the Gleason grading system. Tumor volumes were calculated by the method described previously:
9 the tumor area is measured using a planimeter and multiplied by 5 mm thickness and by a shrinkage correction factor of 1.33. Tumor extent was determined according to the General Rule for Clinical and Pathological Studies on Prostatic Cancer. 10 Briefly, the prostatic capsule on each slide was carefully inspected microscopically for areas of complete cancer penetration through the capsule surface (extracapsular extension). The presence of seminal vesicle involvement or nodal involvement and the status of the surgical margins were also assessed.
Follow-up and end points
After surgery, patients were evaluated at 3-to 6-month intervals with a PSA measurement and digital rectal examination. Bone scans were performed annually. Postoperative PSA values were considered elevated (bF) if values of 0.1 ng/ml or greater were obtained on two consecutive visits. The date of bF was defined as time of the first detectable PSA. If PSA never became undetectable postoperatively, then bF was considered to have occurred at time zero. Systemic progression was defined clinically as the appearance of new lesions on an annual bone scan or appearance of soft-tissue metastasis indicated by biopsy. Causes of death were determined based on hospital records and/or death certificates.
Statistical analysis
w 2 test and simple regression analysis were used to evaluate the relationship between comparisons of variables, with Po0.05 as significant. Survival curves of the patients were compared using the Kaplan-Meier method and analyzed by the log-rank test; the level of significance was again set at 5%. Cox proportional hazards models were used to assess hazard ratio with 95% confidence interval (95%CI) under univariate or multivariate analysis. Log-likelihood ratio test was used to examine whether addition of prostate-specific antigen levels adjusted for total tumor volume (PSA-TTV) density to previously known prognostic factors improved a model's prediction ability. Parameters included age, PSA, tumor volume, specimen Gleason score, pathological category, extracapsular extension, seminal vesicle involvement, nodal involvement, margin status and adjuvant therapy. End points were defined as the advent of bF, systemic failure and death from prostate cancer progression. The interval to each end point was calculated from the date of surgery. All statistical analyses were conducted using STATA8.0 (STATA Corporation, College Station, TX, USA).
Results
Patient characteristics and PSA-TTV density
Median follow-up after surgery in 268 evaluable patients was 84 months (range, 2-152 months). Patient characteristics are listed in ), respectively.
Specimen tumor grade was classified as Gleason score 2-6 in 106 patients (40%), 7 in 108 patients (40%) and 8-10 in 54 patients (20%). Approximately half (n ¼ 125, 47%) had pT3 disease. Extracapsular extension, seminal vesicle involvement, lymph node involvement and positive surgical margins were found in 113 (42%), 46 (17%), 20 (7%) and 99 (40%) of the patients, respectively. Twenty-seven (10%) of these were treated with adjuvant radiation therapy without endocrine manipulation. After bF, 33% of the patients received some type of salvage therapy -local irradiation in 60 patients, endocrine therapy in 33 patients.
PSA-TTV density (ng/ml cm 3 ) was stratified into three groups: Group I, o0.7 (n ¼ 16); Group II, 0.7-6.0 (n ¼ 161) and Group III, 46.0 (n ¼ 91). Cutoff points were set to maximize accuracy of bF prediction using a logrank test. When compared to other groups, Group I patients appeared to have significantly larger tumors (Po0.0001). These tumors also appeared more aggressive, with significantly higher Gleason scores and higher incidences of pT3, extracapsular extension, seminal vesicle involvement, lymph node involvement and positive surgical margins (Po0.05 Figures 1-3 depict Kaplan-Meier projection of survival curves for bF, systemic failure and death from prostate cancer progression for the three PSA-TTV density groups. The log-rank test indicated significant differences between groups for all these end points, with Group I patients appearing to have the most dire prognosis.
Five-year bF-free survival was 27, 57 and 82% for Group I, Group II and Group III, respectively (Po0.0001). Similarly, systemic progression-free and cancer-specific survival of these patients at 5 years were 49, 94 and 96%, and 73, 97 and 99%, respectively (Po0.0001).
Cox proportional hazards model for predicting bF
In univariate analysis, lower PSA-TTV density, higher preoperative PSA, greater total tumor volume, higher Gleason score, pT3, extracapsular extension, seminal vesicle involvement, lymph node involvement and positive surgical margins all indicated a significantly PSA adjusted total tumor volume as a predictor N Hayashi et al greater risk of bF ( Figure 1 Kaplan-Meier bF survival curves for the three PSA-TTV density groups. Group I, o0.7 ng/ml cm 3 ; Group II, 0.7-6.0 ng/ ml cm 3 and Group III, 46.0 ng/ml cm 3 . Statistical significance was estimated using the log-rank test. Figure 2 Kaplan-Meier systemic failure survival curves for the three PSA-TTV density groups. Group I, o0.7 ng/ml cm 3 ; Group II, 0.7-6.0 ng/ml cm 3 and Group III, 46.0 ng/ml cm 3 . Statistical significance was estimated using the log-rank test.
PSA adjusted total tumor volume as a predictor N Hayashi et al significance ( Table 2 ). Age at surgery and adjuvant therapy also remained significant under multivariate analysis. In the log-likelihood ratio test, addition of PSA-TTV density to a Cox proportional model using the variables age, PSA, tumor volume, specimen Gleason score, pathological category, extracapsular extension, seminal vesicle involvement, nodal involvement, margin status and adjuvant therapy produced a significant improvement in the accuracy of bF prediction (P ¼ 0.035).
Cox proportional hazards model for predicting systemic failure and death from prostate cancer
Univariate analyses indicated Group I, larger tumor volume, higher Gleason score, pT3, extracapsular extension, seminal vesicle involvement, lymph node involvement and positive surgical margins were significantly associated with increased risk of systemic failure and cancer-specific death (Table 3) . Preoperative PSA did not show any significant association with these end points. Multivariate analysis indicated lymph node involvement and positive surgical margins were significant for predicting systemic failure (data not shown). No variables were significant in prediction of cancer death.
Discussion
Although the relation of serum PSA values to prostate cancer was recognized 20 years ago, their relation to BPH Figure 3 Kaplan-Meier survival curves for death from prostate cancer for the three PSA-TTV density groups. Group I, o0.7 ng/ ml cm 3 ; Group II, 0.7-6.0 ng/ml cm 3 and Group III, 46.0 ng/ml cm 3 . Statistical significance was estimated using the log-rank test. Abbreviations: CI, confidence interval; HR, hazard ratio; NS, not significant; PSA-TTV, prostate-specific antigen levels adjusted for total tumor volume.
PSA adjusted total tumor volume as a predictor N Hayashi et al became apparent only in the post-PSA screening era. 5 The heterogeneous nature of prostate cancer, together with biological variables such as tumor vascularity and multifocality, may also influence serum PSA levels. Furthermore, it has been shown that poorly differentiated cancers tend to produce less PSA per volume of tumor tissue. 4 Attempts to accurately predict pathological characteristics of prostate cancer solely as a function of serum PSA below 10 ng/ml have thus had little success to date.
We hypothesized that the combination of a large tumor and low serum PSA may reflect an aggressive phenotype irrespective of the amount of BPH; consequently, PSA-TTV density may have prognostic value after radical prostatectomy for prostate cancer. Increasing dedifferentiation of prostate cancer with increasing tumor volume may result in diminution of PSA production by prostate cancer cells, thus perturbing the otherwise expected relationship between serum PSA and tumor volume. Our patients with the lowest PSA-TTV density, o0.7 ng/ml cm 3 (Group I) had a risk of bF 6.3 times that of patients with values of 6.0 ng/ml cm 3 or greater (Group III). This low PSA-TTV patient subset was also at significantly higher risk for systemic progression and cancer death in univariate analysis (Tables 2 and 3 ; Figures 1-3 ). Most (490%) patients in this subset had pathologically advanced cancer with preoperative PSA levels less than 10 ng/ml. Although they represented only about 5% of our patient population, they accounted for approximately one-fifth of high grade (Gleason score 8-10) and large volume (X6.0 cm 3 ) tumors. This patient subset may be different from those in the era before PSA testing, who tended to have poorly differentiated, high volume tumors and advanced disease and may be candidates for more interventional therapeutic approach.
To address the many clinicopathological variables that have been shown to correlate with the likelihood of bF after radical prostatectomy, 1, 6 Kattan et al. 11 developed a postoperative nomogram for disease recurrence. Variables in this nomogram included preoperative PSA, specimen Gleason sum, prostatic capsular invasion, surgical margin status and seminal vesicle and lymph node involvement. Other investigators, however, have emphasized the need to include additional factors, possibly not yet analyzed or determined. 12 In the loglikelihood ratio test, adding PSA-TTV density to the Cox proportional model showed significant (P ¼ 0.035) improvement in bF prediction accuracy. A postoperative nomogram incorporating PSA-TTV density may allow more accurate prediction of treatment outcome.
The advantage of PSA density over PSA for predicting adverse pathological findings and bF after definitive PSA adjusted total tumor volume as a predictor N Hayashi et al therapy for prostate cancer has been reported as marginal to nonexistent. 2, 3 We adjusted PSA levels using tumor volume data measured from the surgical specimen rather than total prostatic volume determined by imaging studies. One of the disadvantages of using values based on tumor volume in a daily practice is the labor-intensive nature of the measurement procedure. Whether values of PSA-TTV calculated using a simpler technique such as tumor volume estimates may provide adequate prognostic accuracy remains to be seen. 13 Our study is limited owing to the small number of patients and its retrospective nature. Numbers of events were too small to examine the independent impact of PSA-TTV density on systemic failure and cancer death. Volumes of the malignant and benign portions of the gland could not be discriminated to accurately assess the importance of PSA-TTV density. Yang et al.
14 demonstrated higher tissue-PSA values in tissue samples from BPH than in samples from prostate cancer. Although this finding may strengthen the impact of PSA-TTV density in this study, measurement and calculation based on the more cancer-specific isoform of PSA may be more informative. 15 Data on serum levels of testosterone in this elderly patient population were not available, 16 so association of free and total testosterone with PSA-TTV density and tumor characterization could not be assessed. More detailed data from a greater number of patients are needed. Further work is warranted.
Conclusions
Patients with low PSA-TTV density levels may represent a subset with dire prognosis after radical prostatectomy and thus may be candidates for a more aggressive therapeutic approach.
